Company news

Co-diagnostics, Inc. (NASDAQ:CODX) news

Every Co-diagnostics, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.

View Co-diagnostics, Inc. stock analysis →

Press releases & updates

Co-Diagnostics Participates in Medical Devices and Innovations Roundtable Media Event

August 18, 2026

Co Diagnostics : Reports Second Quarter 2026 Financial Results

August 13, 2026

Co-Diagnostics Reports Second Quarter 2026 Financial Results

August 13, 2026

Co-Diagnostics Announces Second Quarter 2026 Earnings Release Date and Webcast

July 30, 2026

Co-Diagnostics Joint Venture CoSara Provides Ebola Test Kits for Analytical Studies

July 28, 2026

Co-Diagnostics Joint Venture CoSara Initiates Clinical Studies in India for Tuberculosis Test on PCR Platform

July 22, 2026

Co Diagnostics : Appoints Wes Lindsey, PhD, MBA as Chief Scientific Officer

July 16, 2026

Co-Diagnostics Invited to Participate in NPOC Tuberculosis Diagnostics Workshop in Bangkok, Thailand

July 8, 2026

Co-Diagnostics Vector Smart® Division Expands Footprint to 21 States

June 25, 2026

Co-Diagnostics Hosts Kingdom of Saudi Arabia Joint Venture CoMira for Unveiling of Future Automated Manufacturing Line

June 18, 2026

Co-Diagnostics Advances Latin American Commercialization Strategy for Co-Dx™ PCR Pro® with Mexico Distributor Agreement

June 11, 2026

Co-Diagnostics and CoSara Advance Ebola PCR Test Development and Co-Dx™ PCR Point-of-Care Platform Capabilities

June 2, 2026

Co-Diagnostics Advances Ebola PCR Assay Development Strategy with Joint Venture CoSara

May 26, 2026

Co-Diagnostics Develops Ebola Assay Strategy Following Recent Global Outbreak Alert

May 19, 2026

Co-Diagnostics Reports First Quarter 2026 Financial Results

May 14, 2026

Co-Diagnostics Joint Venture CoMira Finalizes Lease Agreement for Manufacturing Facility in Saudi Arabia's Sudair Industrial City

May 8, 2026

Co-Diagnostics Announces First Quarter 2026 Earnings Release Date and Webcast

April 30, 2026

Co-Diagnostics Invited to Present at Stop TB Partnership Summit in Washington, D.C.

April 16, 2026

Co-Diagnostics to Showcase Co-Dx PCR Platform and CE-IVD Solutions at ESCMID 2026 in Munich, Germany

April 14, 2026

Co-Diagnostics Executives to Participate in European Trade Mission with Utah Governor and WTC Utah

April 9, 2026

Co-Diagnostics Joint Venture CoMira Receives Approval for Manufacturing Facility in Kingdom of Saudi Arabia's Sudair Industrial City

April 2, 2026

Co-Diagnostics Reports Full Year 2025 Financial Results

March 31, 2026

Co-Diagnostics Ships Diagnostic Materials to India for Initiation of Tuberculosis Clinical Studies Following Recently Issued Guidance fro...

March 25, 2026

Co-Diagnostics Signs Agreement to Significantly Expand Commercial and Distribution Territory Across South Asia

March 20, 2026

Co-Diagnostics Announces Fourth Quarter and Full Year 2025 Earnings Release Date and Webcast

March 17, 2026

Co-Diagnostics to Present at Medical Korea 2026

March 16, 2026

Co-Diagnostics Receives Japanese Patent Covering Co-Dx PCR Platform Technologies

March 12, 2026

Co-Diagnostics Regains Compliance with Nasdaq Listing Requirements

March 10, 2026

Co-Diagnostics to Showcase PCR Platform at World Health Expo Labs Dubai

February 9, 2026

Co-Diagnostics Joint Venture CoSara Receives CDSCO License to Manufacture and Sell CoSara PCR Pro™ Instrument

February 5, 2026

Co-Diagnostics JV, CoSara, Receives ISO 13485 Certification in Preparation for Manufacturing Upcoming PCR Platform

February 4, 2026

Co-Diagnostics JV CoSara Participates in Regional Conferences to Grow and Strengthen Distributor Relationships

January 12, 2026

Co-Diagnostics Announces Reverse Stock Split

December 30, 2025

Co-Diagnostics Receives Grant of Australian Patent Covering Co-Dx PCR Platform Technologies

December 29, 2025

Co-Diagnostics Joint Venture, CoSara, Invited to Participate in 2nd Advanced TB Diagnostics Course in Chennai, India

December 18, 2025

Co-Diagnostics Performs Analysis of Influenza Co-Primers® to Confirm Reactivity Against Flu A H3N2 Mutation

December 17, 2025

Co-Diagnostics to Present on Co-Dx™ PCR Platform and AI Integration at Point-of-Care Testing 2025

December 9, 2025

Co-Diagnostics JV, CoSara, to Participate at VIROCON 2025 in Pune, India

December 8, 2025

Co-Diagnostics Delivers Address about Tuberculosis Test Adoption and Implementation at The Union World Conference on Lung Health

November 20, 2025

Co-Diagnostics Initiates Clinical Evaluations for Upper Respiratory Multiplex Point-of-Care Test on Co-Dx™ PCR Platform to Support Submis...

November 18, 2025

Co-Diagnostics Reports Third Quarter 2025 Financial Results

November 13, 2025

Utah Governor Cox and BioUtah Recognize Co-Diagnostics Following Recent JV Announcement in Kingdom of Saudi Arabia

November 12, 2025

Co-Diagnostics Engages Maxim Group to Pursue SPAC Transaction for its Indian Joint Venture, CoSara Diagnostics Pvt. Ltd

November 5, 2025

Co-Diagnostics to Integrate and Implement Proprietary Artificial Intelligence Technology into Co-Dx™ Primer Ai™ Platform

November 3, 2025

Co-Diagnostics, Inc. Announces Third Quarter 2025 Earnings Release Date and Webcast

October 31, 2025

Co-Diagnostics to Host Fireside Chat on November 5th with CEO, Dwight Egan, to Discuss Recently Announced Definitive Agreement in Saudi A...

October 30, 2025

Co-Diagnostics, Inc. Announces Closing of $7.0 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

October 29, 2025

Co-Diagnostics, Inc. Announces Pricing of $7.0 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

October 28, 2025

Co-Diagnostics Signs Definitive Agreement with Arabian Eagle in the Kingdom of Saudi Arabia to Establish CoMira Diagnostics and Localize ...

October 27, 2025

Co-Diagnostics Executive Leadership Team to Attend Global Health Exhibition 2025 in Riyadh, Saudi Arabia

October 22, 2025

Older →